Clinical trials: Docetaxel, completed
Triple-Negative Breast Cancer
Low-dose Apatinib Combined With Neoadjuvant Chemotherapy in the Treatment of Early Triple Negative Breast Cancer
Triple-negative breast cancer (TNBC) is a special type of breast cancer, endocrine therapy and targeted therapy are completely ineffective, chemotherapy is currently the only effective treatment.
- Trial name
- LANCET (NCT03243838)
- Testing
- Apatinib
- Where
- 2 sites in China
- Volunteers
- 31 people
- Sponsor
- Guangdong Provincial People's Hospital
Carcinoma, Non-Small-Cell Lung
VARGADO - Vargatef in 2nd-line Therapy of Non-Small Cell Lung Cancer (NSCLC)
This observational study will investigate the efficacy and tolerability of Vargatef (Nintedanib) plus docetaxel in daily routine second-line treatment in patients with locally advanced, metastatic or locally recurrent NSCLC.
- Trial name
- NCT02392455
- Testing
- treatment
- Where
- Germany
- Volunteers
- 817 people
- Sponsor
- Boehringer Ingelheim
Prostate Cancer
A Salvage Trial of AR Inhibition With ADT and Apalutamide With Radiation Therapy Followed by Docetaxel in Men With PSA Recurrent Prostate Cancer After Radical Prostatectomy (STARTAR)
The purpose of this study is to describe the rate of 3-year progression free survival in men with recurrent PSA-only disease after prostatectomy, who receive combined apalutamide (ARN-509) and standard ADT with salvage radiation…
- Trial name
- NCT03311555
- Testing
- Apalutamide, Androgen deprivation, Salvage radiation therapy
- Where
- 5 sites in United States
- Volunteers
- 39 people
- Sponsor
- Andrew J. Armstrong, MD
Prostate Cancer
Comparison Study of MDX-010 (CTLA-4) Alone and Combined With Docetaxel in the Treatment of Patients With Hormone Refractory Prostate Cancer
The primary objectives of the study are to determine the safety and activity of multiple doses of MDX-010 in patients with hormone-refractory prostate cancer (HRPC), and to determine the safety and activity profile of a single…
- Trial name
- NCT00050596
- Testing
- MDX-010 / MDX-010 + Docetaxel
- Where
- 11 sites in United States
- Sponsor
- Bristol-Myers Squibb
Adenocarcinoma of the Stomach, GastroEsophageal Cancer
Modified FOLFOX Plus/Minus Nivolumab and Ipilimumab vs. FLOT Plus Nivolumab in Patients With Previously Untreated Advanced or Metastatic Gastric Cancer
Patients with Her2 negative, previously untreated metastatic esophagogastric adenocarcinoma will be treated with modified FOLFOX, with modified FOLFOX plus Nivolumab and Ipilimumab or FLOT plus Nivolumab.
- Trial name
- NCT03647969
- Testing
- Nivolumab, Ipilimumab, mFOLFOX
- Where
- 27 sites in Germany
- Volunteers
- 262 people
- Sponsor
- Institut für Klinische Krebsforschung IKF GmbH at Krankenhaus Nordwest
Castration Levels of Testosterone, Castration-Resistant Prostate Carcinoma
Docetaxel and Carboplatin in Treating Patients With Metastatic, Castration Resistant Prostate Cancer Containing Inactivated Genes in the BRCA 1/2 Pathway
This pilot clinical trial studies docetaxel and carboplatin in treating patients with castration resistant prostate cancer that has spread from the primary site (place where it started) to other places in the body (metastatic)…
- Conditions
- Castration Levels of Testosterone, Castration-Resistant Prostate Carcinoma, Metastatic Prostate Carcinoma, Prostate Carcinoma Metastatic in the Bone
- Trial name
- NCT02598895
- Testing
- Carboplatin, Docetaxel, Laboratory Biomarker Analysis
- Where
- United States
- Volunteers
- 14 people
- Sponsor
- University of Washington
Head and Neck Squamous Cell Carcinoma
Treatment of Patients With Locally Advanced Squamous Cell Carcinoma of the Head and Neck
This is a randomized multicenter open label phase III factorial trial evaluating the 3 years OS in patients with locally advanced squamous cell carcinoma of head and neck treated with locoregional treatment (radiotherapy plus…
- Trial name
- H&N07 (NCT01086826)
- Testing
- RT+CDDP/5-FU, RT+CETUXIMAB, INDUCTION CTx(TPF)+(RT+CDDP/5-FU)
- Where
- 60 sites in Italy
- Volunteers
- 320 people
- Sponsor
- Associazione Volontari Pazienti Oncologici
Metastatic Prostate Cancer
A Phase 2 Trial of Bevacizumab, Lenalidomide, Docetaxel, and Prednisone (ART-P) for Treatment of Metastatic Castrate-Resistant Prostate Cancer
Background: Prednisone and docetaxel have been used successfully in treating patients with prostate cancer, either when used alone or in combination with other agents.
- Trial name
- NCT00942578
- Testing
- Bevacizumab, Lenalidomide, Docetaxel
- Where
- United States
- Volunteers
- 63 people
- Sponsor
- National Cancer Institute (NCI)
Breast Cancer, Neoplasm Metastasis
Liposomal Doxorubicin and Docetaxel in HER2 Negative Metastatic Breast Cancer
This is an open phase II multicentre study evaluating the efficacy and safety of the non pegylated liposomal doxorubicin (Myocet®) and docetaxel (Taxotere®) combination as first-line treatment of patients with metastatic HER2/neu…
- Trial name
- MYOTAX (NCT00377559)
- Testing
- Non pegylated liposomal doxorubicin and docetaxel
- Where
- 10 sites in Netherlands
- Volunteers
- 70 people
- Sponsor
- Catharina Ziekenhuis Eindhoven
Esophageal Cancer, Adenocarcinoma, Esophageal
Preoperative Chemotherapy vs. Chemoradiation in Esophageal / GEJ Adenocarcinoma
The best treatment for resectable esophageal or gastroesophageal adenocarcinoma is unknown. Although an operation to remove the esophagus is the most common treatment, previous studies have shown that patients live longer when…
- Conditions
- Esophageal Cancer, Adenocarcinoma, Esophageal, Adenocarcinoma, Gastroesophageal Junction
- Trial name
- POWERRANGER (NCT01404156)
- Testing
- (Epirubicin Cisplatin 5-Fluorouracil / Xeloda) OR 5-Fluorouracil Leucovorin Oxaliplatin Docetaxel, Carboplatin paclitaxel plus concurrent radiotherapy
- Where
- 3 sites in Canada
- Volunteers
- 29 people
- Sponsor
- Dr. Gordon Buduhan
Resectable Gastric or Gastroesophageal Junction Adenocarcinoma
Trial of Neoadjuvant Durvalumab Plus Docetaxel, Oxaliplatin, S-1 Followed by Surgery and Adjuvant Durvalumab Plus S-1 Chemotherapy in Potentially Resectable MMR Proficient Gastric or Gastroesophageal Junction Adenocarcinoma
Neoadjuvant durvalumab (MEDI4736) plus docetaxel, oxaliplatin, S-1 (DOS) followed by surgery and adjuvant durvalumab plus S-1 chemotherapy in potentially resectable MMR proficient (pMMR) gastric or gastroesophageal junction (GEJ)…
- Trial name
- NCT04221555
- Testing
- Docetaxel, Oxaliplatin, S-1 and Durvalumab, Durvalumab and Tremelimumab
- Where
- South Korea
- Volunteers
- 68 people, healthy volunteers welcome
- Sponsor
- Asan Medical Center
Prostate Cancer
Docetaxel and Prednisone With/Out OGX-011 in Recurrent or Metastatic Prostate Cancer That Did Not Respond to Previous Hormone Therapy
RATIONALE: Drugs used in chemotherapy, such as docetaxel and prednisone, work in different ways to stop the growth of tumor cells, either by killing the cells or by stopping them from dividing.
- Trial name
- NCT00258388
- Testing
- custirsen sodium, docetaxel, prednisone
- Where
- 13 sites in United States, Canada
- Volunteers
- 82 people
- Sponsor
- NCIC Clinical Trials Group
Solid Cancers
A Study to Evaluate Corrected QT Interval and Drug-Drug Interaction of Trastuzumab on Carboplatin in the Presence of Docetaxel in Patients With HER2-Positive Metastatic or Locally Advanced Inoperable Cancer
This Phase Ib, multicenter, single-arm, open-label study is designed to evaluate the effect of trastuzumab on QTcF interval and to characterize the effects of trastuzumab on carboplatin pharmacokinetics in patients with…
- Trial name
- NCT00927589
- Testing
- carboplatin, docetaxel, trastuzumab
- Where
- 20 sites in United States
- Volunteers
- 59 people
- Sponsor
- Genentech, Inc.
Cancer
Weekly Administration of (bi-)Daily Oral Docetaxel in Combination With Ritonavir
Oral administration has many advantages above intravenously administrated drugs for patients. Up to now, oral administration of docetaxel as single agent has not been feasible due to low and variable bioavailability.
- Trial name
- NCT01173913
- Testing
- ModraDoc001 10mg capsules, ModraDoc003 10mg tablets and ModraDoc004 10/50 mg, ModraDoc006 10 mg tablet
- Where
- Netherlands
- Volunteers
- 57 people
- Sponsor
- The Netherlands Cancer Institute
Unspecified Adult Solid Tumor, Protocol Specific
Docetaxel and Irinotecan in Treating Patients With Advanced Solid Tumors
RATIONALE: Drugs used in chemotherapy use different ways to stop tumor cells from dividing so they stop growing or die. Combining more than one drug may kill more tumor cells.
- Trial name
- NCT00004923
- Testing
- docetaxel, irinotecan hydrochloride
- Where
- 2 sites in United States
- Volunteers
- 47 people
- Sponsor
- Yale University
Prostate Cancer
A Study to Determine the Maximum Tolerated Dose of Elesclomol Sodium Given With a Fixed Dose of Docetaxel and Prednisone in Patients With Metastatic Prostate Cancer
This aim of this study is to determine the safety and tolerability of elesclomol sodium at escalating doses (ultimately identifying the maximum tolerated dose) when combined with a fixed dose of docetaxel and concomitant…
- Trial name
- NCT00808418
- Testing
- Elesclomol Sodium, Docetaxel
- Where
- 5 sites in United States
- Volunteers
- 34 people
- Sponsor
- Synta Pharmaceuticals Corp.
Head and Neck Cancer
Gemcitabine and Docetaxel in Treating Patients With Persistent, Recurrent, or Metastatic Head and Neck Cancer
RATIONALE: Drugs used in chemotherapy, such as gemcitabine and docetaxel, work in different ways to stop the growth of tumor cells, either by killing the cells or by stopping them from dividing.
- Trial name
- NCT00248560
- Testing
- docetaxel, Gemcitabine
- Where
- United States
- Volunteers
- 36 people
- Sponsor
- Barbara Ann Karmanos Cancer Institute
Pathological Response Rate
Assessment of the Efficacy of the Neoadjuvant Combination: "Chemotherapy-Targeted Therapy" in Breast Cancer.
The purpose of this study is to assess the pathological response rate in operable breast cancer patients treated by neoadjuvant combination: "FEC-Taxotere/Vectibix".
- Trial name
- TVA (NCT00933517)
- Testing
- vectibix, fluorouracile, Epirubicine
- Where
- 12 sites in France
- Volunteers
- 62 people
- Sponsor
- Centre Jean Perrin
Non-small Cell Lung Cancer
Erlotinib Treatment Beyond Progression in EGFR Mutant NSCLC
The purpose of this study is to determine whether continuing erlotinib beyond disease progression in combination with chemotherapy is beneficial for NSCLC patients who have EGFR mutant disease or who have responded to EGFR TKI.
- Trial name
- NCT02064491
- Testing
- Erlotinib, Chemotherapy
- Where
- 7 sites in Finland
- Volunteers
- 18 people
- Sponsor
- Finnish Lung Cancer Group
Prostate Cancer
Immunotherapy After Chemotherapy for Patients With Hormone Refractory Metastatic Prostate Cancer
The purpose of this study is to test if interleukin-2, a drug that stimulates the immune system, can be used after chemotherapy to slow the progression of your disease.
- Trial name
- NCT00283829
- Testing
- docetaxel, IL2
- Where
- United States
- Volunteers
- 30 people
- Sponsor
- University of Washington
The first 1,020 results can be paged through. Add a filter or change the sort order to reach the rest.